Cybin (NASDAQ:HELP) Releases Quarterly Earnings Results, Misses Estimates By $0.19 EPS

Cybin (NASDAQ:HELP) issued its quarterly earnings results on Friday. The company reported ($0.72) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.19), Zacks reports.

Cybin Price Performance

HELP stock traded up $0.21 during trading on Friday, reaching $6.13. 163,432 shares of the stock were exchanged, compared to its average volume of 503,340. The company has a debt-to-equity ratio of 0.21, a current ratio of 8.58 and a quick ratio of 8.58. The company has a market capitalization of $305.83 million, a PE ratio of -1.58 and a beta of 0.63. Cybin has a 1 year low of $4.81 and a 1 year high of $10.59.

Analyst Ratings Changes

Separately, Jefferies Financial Group started coverage on Cybin in a report on Monday, February 2nd. They set a “buy” rating and a $22.00 target price for the company. One research analyst has rated the stock with a Buy rating, According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $22.00.

Cybin Company Profile

Cybin Inc is a clinical-stage biopharmaceutical company focused on the development of psychedelic-based therapeutics for the treatment of mental health disorders. Headquartered in Toronto and listed on the NASDAQ under the symbol HELP, Cybin pursues research and development programs intended to harness the therapeutic potential of psychedelic compounds to address conditions with significant unmet need.

The company operates a drug discovery and development platform aimed at creating novel small-molecule psychedelic analogs and tailored formulations.